{
    "nctId": "NCT00365599",
    "briefTitle": "Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer",
    "officialTitle": "Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) in Combination With Tamoxifen for Patients With Advanced Breast Cancer Who Have Failed Prior Anti-hormonal Therapy.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 43,
    "primaryOutcomeMeasure": "Number of Participants With Objective Response (OR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have cytologically/histologically documented locally advanced or metastatic breast cancer with either:\n\n  1. Progression on treatment with any aromatase inhibitor for metastatic disease;\n  2. Recurrence while on adjuvant aromatase inhibitors or within 12 months of completion;\n  3. Recurrence after having completed adjuvant tamoxifen for at least 12 months;\n  4. Patient who are not candidates for or are intolerant of aromatase inhibitor treatment;\n  5. Patients are allowed (but not required) to have one prior chemotherapy regimen for metastatic disease.\n* Tumors must express estrogen or progesterone receptor.\n* Patients are eligible regardless of the menopausal status.\n* Age \\> 18 years old\n* Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Patients must be able to give informed consent and able to follow guidelines given in the study.\n* Patients must have acceptable organ function, as defined by the following laboratory parameters: white blood count (WBC) \\>3.0 x 10\\^9/L; absolute neutrophil count (ANC) \\>1.5 x 10\\^9/L; hemoglobin (Hgb) \\>10.0g/dL; platelets (PLT) \\>100 x 10\\^9/L, Bilirubin \\< 2.0 mg/dl, aspartate aminotransferase/alanine aminotransferase (AST/ALT) \\< 2.5 X upper limit of normal (ULN), Creatinine \\<1.8 mg/dl (Creatinine clearance \\>60 ml/min).\n* Women of childbearing age must have a negative pregnancy test. All patients of reproductive potential must use an effective method of contraception during the study and 6 months following termination of treatment. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to female patients who are older than 50 years and have not had a menstrual cycle in more than one year.\n* Patients must have measurable disease by RECIST criteria by staging studies performed within 30 days of enrollment. For patients with bone only disease: For this protocol isolated bone lesions can be classified as target lesions if they are measurable by MRI at screening and must be followed by MRI.\n* Both men and women of all races and ethnic groups are eligible for this trial.\n\nExclusion Criteria:\n\n* Patients must not have received tamoxifen for metastatic disease.\n* Patients must not have evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry.\n* Patients must be disease-free of prior invasive malignancies for \\> 5 years with the exception of: curatively-treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix.\n* Pregnant and breast-feeding women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage.\n* Patients with uncontrolled central nervous system (CNS) metastasis or a history of seizures are excluded. Patients with stable CNS metastasis (either surgically resected, treated with gamma knife or stable for 3 months following whole brain radiation therapy \\[WBRT\\] are eligible). Patients with stable brain metastases will need an MRI within 4 weeks prior to start of therapy.\n* Patients may not be receiving any other investigational agents and must have stopped all other histone deacetylase inhibitors (including Valproic acid) or other hormonal therapies.\n* Patients must have discontinued their prior therapies for breast cancer and radiation therapy for a minimum of 3 weeks, patient is excluded if radiation therapy was given to a single measurable lesion and the disease is otherwise not measurable.\n* Patients are excluded if they have any known hypersensitivity reaction to tamoxifen.\n* Patient with a history of blood clots are not eligible.\n* Women who have abnormal vaginal bleeding and/or endometrial hyperplasia or cancer are not eligible.\n* Patients with evidence of visceral crisis are not eligible for this study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}